Zimmer Biomet Holdings Inc. (NYSE:ZBH) finished Friday with a subtraction of -$0.39 to close at $150.42, a downside of -0.26 percent. An average of 838,420 shares of common stock have been traded in the last five days. There was a gain of $4.06 in the past week, and it reached a new high 11 times over the past 12 months. The last 20 days have seen an average of 983,815 shares traded, while the 50-day average volume stands at 1,332,232.
ZBH stock has increased by 0.01% in the last month. The company shares reached their 1-month lowest point of $141.47 on 10/13/21. With the stock rallying to its 52-week high on 04/29/21, shares of the company touched a low of $130.05 and a high of $180.36 in 52 weeks. It has reached a new high 15 times so far this year and lost -2.38% or -$3.67 in price. In spite of this, the price is down -16.60% from the 52-week high.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
339 days have passed since Zimmer Biomet Holdings Inc. (ZBH) last reported insider trading activity. Yi Sang, who is President, Asia Pacific, most recently acquired $1,200 shares at $152.59 per share on Nov 18. In this transaction, the insider spent $183,108. Sr. VP/Gen Counsel/Secretary, Phipps Chad F, disposed of 30,040 shares at a price of $159.70 on Nov 09. The insider now owns more than $4,797,388 worth of shares.
Zimmer Biomet Holdings Inc. (ZBH) has a trailing price-to-earnings (P/E) ratio of 33.72, which compares with the 26.30 for the broader industry and 33.43 for the sector. In the last five years, Zimmer Biomet Holdings Inc.’s PE ratio has ranged between 912.06 and 11.18. The stock’s beta is 1.25. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 3.96, the price-to-book (PB) ratio at 2.49, and the price-to-cash flow ratio at 26.17.
Zimmer Biomet Holdings Inc. pays a $0.96 dividend per share annually. It offers a dividend yield of 0.64%. The company has a payout ratio of 21.80%. The company’s most recent quarterly dividend payment was $0.24 a share, without any change from last year. Its dividend has been increased for the last 1 year with the latest increase dividend $0.02 reported on Wednesday February 24 2016.
The quick ratio of Zimmer Biomet Holdings Inc. for the three months ended June 29 was 1.00, and the current ratio was 1.80, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.54 and a total debt to equity ratio of 0.62 for the quarter ending June 29. Zimmer Biomet Holdings Inc.’s EBITDA margin for the year ending June 29 is 26.27%, while its operating margin for the same period stands at 13.00%. Its gross profit as reported stood at $4.9 billion compared to revenue of $7.02 billion.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Zimmer Biomet Holdings Inc.’s return on assets was 3.80%. For the broader industry, ROE averaged 3.96 over the past year.
For the three-month period that ended June 29, Zimmer Biomet Holdings Inc. had $6.8 billion in total debt. In the quarter under review, the net income was up than the previous quarter. The company posted a net income of $141.9 million in the quarter, while revenues of $198.1 million were grew 245.6%. The analyst consensus anticipated Zimmer Biomet Holdings Inc.’s latest quarter earnings to come in at $1.87 per share, but it turned out to be $1.9, a 1.60% surprise. For the quarter, EBITDA amounted to $503.3 million. Shareholders own equity worth $208.84 million.
From a technical analysis perspective, let’s take a brief look at Zimmer Biomet Holdings Inc. (ZBH) price momentum. RSI 9-day as of the close on 22 October was 62.11%, suggesting the stock is Neutral, with historical volatility in this time frame at 17.44%.
As of today, ZBH’s price is $149.05 +2.77% or $4.06 from its 5-day moving average. ZBH is currently trading -0.54% lower than its 20-day SMA and -6.61% lower than its 100-day SMA. However, the stock’s current price level is +2.74% above the SMA50 and -5.57% below the SMA200.
The stochastic %K and %D were 88.91% and 81.91%, respectively, and the average true range (ATR) was 3.06. With the 14-day stochastic at 87.23% and the average true range at 3.17, the RSI (14) stands at 57.24%. The stock has reached 3.47 on the 9-day MACD Oscillator while the 14-day reading was at 3.79.
The consensus rating for Zimmer Biomet Holdings Inc. (ZBH) among analysts is Overweight. According to current brokerage recommendations, 1 brokerage firm advise that investors sell ZBH, while 5 suggest investors hold. There are 1 analyst who rate the stock as underweight. The stock is rated overweight by 2 analysts, while 21 others rate it as a “buy”.
What is ZBH’s price target for the next 12 months?
Analysts predict a range of price targets between $134.00 and $205.00, with a median target of $188.00. Taking a look at these predictions, the average price target given by analysts for Zimmer Biomet Holdings Inc. (ZBH) stock is $184.50.